Development of effective anti-influenza drugs: congeners and conjugates – a review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1423-0127
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Development of effective anti-influenza drugs: congeners and conjugates – a review ; volume:26 ; number:1 ; day:23 ; month:10 ; year:2019 ; pages:1-20 ; date:12.2019
Journal of biomedical science ; 26, Heft 1 (23.10.2019), 1-20, 12.2019
- Urheber
-
Shie, Jiun-Jie
Fang, Jim-Min
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12929-019-0567-0
- URN
-
urn:nbn:de:101:1-2020021617550348980514
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shie, Jiun-Jie
- Fang, Jim-Min
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody Drug Conjugates
RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
Oligosaccharides based antibacterial drug conjugates
Multivalent Peptide–Nanoparticle Conjugates for Influenza‐Virus Inhibition
Development and characterization of anti-EGFR protein-drug conjugates for tumor therapy
Ribavirin is effective against drug-resistant H7N9 influenza virus infections
Antibody–drug conjugates in ovarian cancer
Chemoselective synthesis of functional drug conjugates
Antibody–drug conjugates—the magic bullet?
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Antibody Drug Conjugates
RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
Oligosaccharides based antibacterial drug conjugates
Multivalent Peptide–Nanoparticle Conjugates for Influenza‐Virus Inhibition
Development and characterization of anti-EGFR protein-drug conjugates for tumor therapy
Ribavirin is effective against drug-resistant H7N9 influenza virus infections
Antibody–drug conjugates in ovarian cancer
Chemoselective synthesis of functional drug conjugates
Antibody–drug conjugates—the magic bullet?
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Antibody Drug Conjugates
RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
Oligosaccharides based antibacterial drug conjugates
Multivalent Peptide–Nanoparticle Conjugates for Influenza‐Virus Inhibition
Development and characterization of anti-EGFR protein-drug conjugates for tumor therapy
Ribavirin is effective against drug-resistant H7N9 influenza virus infections
Antibody–drug conjugates in ovarian cancer
Chemoselective synthesis of functional drug conjugates
Antibody–drug conjugates—the magic bullet?